^
Association details:
| Biomarker: | ALK positive + ERCC3 E259D + GNAS A436_P459del |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Dynamic monitoring of circulating tumor DNA to analyze genetic characteristics and resistance profile of lorlatinib in ALK positive previously treated NSCLC
Published date:
06/02/2023
Excerpt:
In patient P2, DNMT3A N403Tfs*4 was only detected at T2 when the tumor progressed (Figure 4a). In patient P9, ERCC3 E259D and GNAS p.A436_P459del were present after progression on lorlatinib...
DOI:
https://doi.org/10.1111/1759-7714.14980
